ghrelin: the endogenous hunger hormone and GHS-R agonist

ghrelin is a 28-amino-acid peptide hormone produced primarily by specialized enteroendocrine cells (X/A-like cells) in the gastric fundus. it is the endogenous ligand of GHS-R1a, a G protein-coupled receptor expressed broadly in the hypothalamus, pituitary, and throughout the cardiovascular and gastrointestinal systems. it was discovered in 1999 by Kojima and colleagues, who identified it as the long-sought natural ligand of a receptor that synthetic GH secretagogues had been activating for years before the endogenous signal was known.

what is ghrelin?

ghrelin is the body's principal hunger signal. levels rise sharply before meals and fall within 30 to 60 minutes of eating. it is the only known circulating hormone that potently stimulates appetite in humans. it also drives growth hormone release from the pituitary, making it a point of intersection between the energy-sensing and growth-signaling systems.

the name "ghrelin" is derived from "ghre," a Proto-Indo-European root meaning "growth," combined with "relin" from the word release. the peptide is 28 amino acids long and carries an unusual post-translational modification: a fatty acid chain, usually octanoic acid (an 8-carbon saturated fat), is attached via an ester bond to the serine residue at position 3. this modification, called octanoylation or n-octanoylation, is catalyzed by the enzyme GOAT (ghrelin O-acyltransferase) and is essential for receptor binding. without it, the peptide is called des-acyl ghrelin and does not bind GHS-R1a, though it has its own biological activities through other, less characterized pathways [1].

the acyl modification makes ghrelin unusual among peptide hormones. most peptide hormones rely entirely on their amino acid sequence for receptor recognition. ghrelin's requirement for fatty acid acylation means that GOAT enzyme activity is a regulatory point for the hormone's potency, and that synthetic ghrelin analogs must either incorporate or mimic this modification to be active at GHS-R1a.

discovery and the GHS-R story

ghrelin was discovered in 1999 as the natural ligand of GHS-R1a, a receptor that had been identified years earlier through its response to synthetic GH secretagogues. the receptor had been named before its natural ligand was found -- an example of pharmacology revealing receptor biology before biochemistry identified the hormone.

the growth hormone secretagogue receptor (GHS-R1a) was first characterized in the 1990s through experiments with synthetic compounds, including the hexapeptide GHRP-6 and non-peptide analogs, that were discovered to potently release growth hormone from the pituitary by a mechanism distinct from GHRH. these compounds were called "growth hormone secretagogues" (GHS), and their receptor was cloned in 1996 before its natural ligand was known. Kojima and colleagues at Kurume University in Japan searched systematically for the endogenous compound that activated this orphan receptor, identifying ghrelin in rat stomach in 1999. the discovery established that the stomach, not just the hypothalamus, is an important source of hormonal signals regulating the GH axis and energy metabolism [2].

Yamada's 2021 review in the International Journal of Molecular Sciences summarizes the current understanding of GHS-R1a biology. the receptor is a G protein-coupled receptor (GPCR) that, when activated by ghrelin, drives intracellular signaling cascades involving Gq proteins, phospholipase C, and calcium mobilization. GHS-R1a has constitutive activity (it signals even without ligand) and is expressed throughout the hypothalamus, pituitary, hippocampus, heart, and gastrointestinal tract, explaining ghrelin's unusually broad range of physiological effects [1].

what does ghrelin do?

ghrelin's principal roles are appetite stimulation and GH release. beyond those two headline functions, the hormone has documented effects on glucose metabolism, cardiac function, gastrointestinal motility, and stress responses. it also shows sex-dependent variation in its signaling, with differences in how GHS-R1a responds to physiological stress in males versus females.

the orexigenic effect is the function most people associate with ghrelin. levels peak in the 30 to 90 minutes before a habitual meal time and fall sharply within 30 minutes of eating. this pre-meal ghrelin spike acts on hypothalamic circuits (primarily neuropeptide Y/AgRP neurons) to drive hunger. the stomach is the dominant source of circulating ghrelin, which is why gastrectomy (stomach removal) dramatically reduces fasting ghrelin levels, and why patients who undergo certain bariatric procedures show markedly reduced ghrelin responses that may contribute to long-term appetite suppression.

the GH-releasing effect occurs through GHS-R1a receptors on pituitary somatotropes. ghrelin acts synergistically with GHRH: GHRH primes the somatotrope, and ghrelin amplifies the GH pulse. this is mechanistically distinct from GHRH analogs like sermorelin or tesamorelin, which act at the GHRH receptor rather than GHS-R1a. the combination of GHRH-receptor and GHS-R1a stimulation produces larger GH pulses than either alone, which is the mechanistic rationale for combining GHRP-class peptides with GHRH analogs in research contexts.

Tokudome, Miyazato, and Kangawa's 2019 review in Peptides covers ghrelin's cardiac and cardiovascular effects. ghrelin administration in animal models improves cardiac function in chronic heart failure, reduces pulmonary hypertension, and lowers arrhythmia frequency following myocardial infarction. in cachexia associated with COPD, ghrelin treatment in small human studies produced metabolic benefits. the authors characterize ghrelin as "a promising novel therapeutic agent for cardiac disease," though no ghrelin-based drug has yet reached approval for cardiovascular indications [2].

ghrelin also modulates glucose metabolism. it generally raises blood glucose by opposing insulin action, which is mechanistically consistent with its role in anticipatory feeding preparation. the relationship between ghrelin and diabetes risk has been studied, with fasting ghrelin showing inverse correlations with insulin resistance in some populations. Poher, Tschop, and Muller's review in Peptides (2018) covered ghrelin's metabolic functions in detail, documenting both glucose-raising and body-weight-influencing effects across animal and human studies [3].

acylated ghrelin versus des-acyl ghrelin

the two circulating forms of ghrelin have different and in some respects opposing biological profiles. acylated ghrelin (the GHS-R1a-active form) stimulates appetite and GH release. des-acyl ghrelin does not bind GHS-R1a and in some animal studies appears to have anti-orexigenic or insulin-sensitizing effects. the interplay between the two forms is an active area of research.

in the circulation, des-acyl ghrelin is quantitatively dominant, comprising roughly 80 to 90 percent of total ghrelin. acylated ghrelin represents the smaller, receptor-active fraction. the GOAT enzyme is the gate controlling the ratio. dietary fat content affects GOAT activity, providing a potential mechanism by which meal composition influences ghrelin potency.

the structural determinants of GHS-R1a recognition have been studied by Shiimura, Kojima, and Sato in a 2025 paper in Frontiers in Molecular Neuroscience. their structural work describes exactly how the acylated ghrelin peptide docks into GHS-R1a, providing molecular-level clarity on why the octanoyl modification at Ser3 is essential for receptor activation. this kind of structural insight is what guides the design of synthetic analogs with modified pharmacokinetics [4].

synthetic ghrelin analogs and research use

because endogenous ghrelin has a short circulating half-life of approximately 30 minutes and requires precise acylation for activity, therapeutic and research applications have pursued synthetic analogs with improved stability, modified receptor selectivity, or oral bioavailability. GHS-R1a agonists and antagonists are being studied for cancer cachexia, gastroparesis, cardiac failure, and eating disorders.

the GHRP family -- GHRP-2 and GHRP-6 -- are structurally unrelated to ghrelin but activate GHS-R1a and produce overlapping effects. they were developed before ghrelin's discovery and can be understood in retrospect as the first synthetic GHS-R1a agonists. neither is FDA-approved, and both are used primarily in research and off-label in compounding pharmacy contexts.

macimorelin is a synthetic oral GHS-R1a agonist that received FDA approval in 2017 for the diagnosis of adult growth hormone deficiency (AGHD), not for therapeutic growth hormone release. it is the only GHS-R1a agonist with any FDA approval, and its approved use is purely diagnostic: a single oral dose stimulates GH release, and the peak GH response is used to confirm or exclude AGHD. it is not approved as a therapeutic agent and is not used for body composition or performance purposes.

GHS-R1a antagonists are also under investigation, for the opposite purpose: blocking ghrelin signaling to reduce appetite in obesity. no GHS-R1a antagonist has reached approval. the field competes with the more clinically mature GLP-1 receptor agonist class (including semaglutide and tirzepatide), which have already reached regulatory approval for obesity, making the GHS-R antagonist development pathway commercially challenging.

for basic researchers, synthetic stable ghrelin analogs serve as tools to study GHS-R1a function in models of muscle wasting, cardiac disease, and appetite circuitry. their use in research settings is legitimate and important; any discussion of using synthetic ghrelin agonists outside a research or clinical context requires the same evidence scrutiny applied to any unapproved peptide.

where ghrelin fits in the peptide landscape

ghrelin is the endogenous reference point for the entire GHS-R1a pharmacology space. it is mechanistically distinct from GHRH-axis peptides (sermorelin, CJC-1295, tesamorelin) but complementary to them in GH regulation. it sits on the opposite side of the appetite axis from GLP-1 (anorexigenic) and NPY (also orexigenic through different circuits). understanding ghrelin is foundational to understanding both growth hormone secretagogue research and appetite-modulating peptide biology.

for a side-by-side view of how the GH axis peptides (GHRH analogs, GHRPs, ghrelin) relate mechanistically, the muscle-building peptides guide provides a useful landscape overview. the GLP-1 comparison blog covers the opposite pole of the appetite-regulation axis. and the nesfatin-1 page covers another endogenous appetite-modulating peptide, this time with anorexigenic effects, for contrast.